|
End-of-day quote
Shanghai S.E.
2026-10-16
|
5-day change | 1st Jan Change | ||
| 6.320 CNY | +2.10% |
|
-14.48% | +83.19% |
| 10-13 | Harbin Pharmaceutical Subsidiary Gets China Approval for Sodium Sulfate API | MT |
| 08-25 | Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
Evolution of the Average Target: Harbin Pharmaceutical Group Co., Ltd.
Evolution of the Target Price: Harbin Pharmaceutical Group Co., Ltd.
Changes in Analyst Recommendations: Harbin Pharmaceutical Group Co., Ltd.
f88494c541.KZf87VbRavCTdsLd7oWTBZml8QLKdc-fPHpxIU3wZqo.Yfy5oCS6ErqhNaiEnNHFXcjGhUOoRKH8BRYHcnSVBOtdopm0JL4-hvwxtQ~59392b0aa291e10789d39ac7a2f3289c
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | - | - | +44.94% | |||
| +5.65% | |||||
| +9.33% | |||||
| -0.99% | |||||
| -0.52% | |||||
| +8.56% | |||||
| -0.8% | |||||
| +26.78% | |||||
| -8.67% | |||||
| +2.34% | |||||
| Average | +8.66% | |||||
| Weighted average by Cap. | +4.99% |
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
6.320CNY
Average target price
9.160CNY
Spread / Average Target
+44.94%
High Price Target
9.160CNY
Spread / Highest target
+44.94%
Low Price Target
9.160CNY
Spread / Lowest Target
+44.94%
Analyst Consensus Detail
Consensus revision (last 18 months)
- Stock Market
- Stocks
- 600664 Stock
- Consensus Harbin Pharmaceutical Group Co., Ltd.
Select your edition
All financial news and data tailored to specific country editions
